The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GD2/GD3 expression: Companion diagnostic for ganglioside-targeted immunotherapy against pediatric solid tumors.
 
Konstantin Dobrenkov
No Relationships to Disclose
 
Irina Ostrovnaya
No Relationships to Disclose
 
Irene Y. Cheung
Stock and Other Ownership Interests - Ymabs Therapeutics Inc (I)
Honoraria - AstraZeneca (I)
Patents, Royalties, Other Intellectual Property - Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof (I); Biotec pharmacon (I); Bispecific HER2 and CD3 binding molecules (I); GD2 peptide mimics (I); Methods for detecting MRD (Inst); Novartis:Generation and use of HLA-A2-restricted peptide-specific mAbs and CARS (I); ROR2 antibodies (I)
 
Yi Feng
No Relationships to Disclose
 
Nai-Kong V. Cheung
Consulting or Advisory Role - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - affinity matured hu8H9 (Inst); anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof (Inst); anti-GD2 antibodies (Inst); bispecific HER2 and CD3 binding molecules (Inst); GD2 peptide mimics (Inst); generation and use of HLA-A2–restricted peptide-specific mAbs and CARs (Inst); high-affinity anti-GD2 antibodies (Inst); methods for detecting MRD (Inst); methods for preparing and using scFv (Inst); multimerization technologies (Inst); ROR2 antibodies (Inst); scfv constructs of anti-GD2 antibodies (Inst); therapy-enhancing glucan (Inst); use of mAb 8H9 (Inst)